[Hiring] Medical Director, Medical Affairs @Compass Pathways

Role Description

The Medical Director, Medical Affairs will serve as a subject matter expert representing professional medical expertise within the Medical Affairs function, with an initial focus on treatment-resistant depression (TRD) and investigational psychedelic therapeutics. This individual will provide clinical perspective, medical judgment, and thought partnership to Medical Affairs leadership and functional teams.

The Medical Director will contribute to the execution of Medical Affairs strategy through critical evaluation of clinical evidence, development of evidence-generation initiatives, and engagement with external medical experts. Working collaboratively with Medical Affairs and cross-functional partners, the Medical Director will help ensure that scientific initiatives are clinically relevant, evidence-based, and responsive to evolving needs in psychiatric care.

The successful candidate will bring deep expertise in psychiatry, the ability to critically analyze emerging evidence, and established relationships within the medical and scientific community. This individual will be expected to proactively identify important clinical knowledge gaps, recommend approaches to addressing them, and take an active role in developing and advancing research initiatives that inform clinical practice.

Qualifications

• MD or DO degree from an accredited medical institution
• Clinical training and demonstrated expertise in psychiatry, with strong knowledge of treatment-resistant depression and contemporary psychiatric treatment approaches
• Experience in clinical research, academic medicine, pharmaceutical development, Medical Affairs, or a related scientific or clinical setting
• Demonstrated ability to critically evaluate clinical research, interpret complex data, and communicate findings to diverse medical and scientific audiences
• Experience contributing to clinical research, scientific publications, medical education, or other evidence-generation activities
• Strong understanding of clinical research methodology, evidence-based medicine, and principles of scientific communication
• Excellent interpersonal, communication, and collaboration skills, with the ability to engage effectively with senior medical and scientific stakeholders
• Demonstrated ability to manage multiple initiatives and work effectively across multidisciplinary teams

Requirements

• Board certification in Psychiatry (preferred)
• Experience in interventional psychiatry, including clinical or research experience with treatments such as esketamine, ketamine, transcranial magnetic stimulation, electroconvulsive therapy, or psychedelic therapeutics (preferred)
• Prior experience in pharmaceutical or biotechnology Medical Affairs, Clinical Development, or a related industry function (preferred)
• Experience developing research proposals, clinical protocols, real-world evidence studies, or investigator-initiated research programs (preferred)
• Established relationships within psychiatry, particularly in TRD, interventional psychiatry, or emerging psychiatric therapeutics (preferred)
• Experience leading scientific advisory boards, expert consensus initiatives, or other external scientific collaborations (preferred)
• Familiarity with pharmaceutical medical review processes, MLR governance, and regulatory requirements governing scientific communications (preferred)
• Experience supporting late-stage clinical development, product launch preparation, or early commercialization activities (preferred)

Benefits

• Flexibility & generous time off
• Parental & reproductive support
• Health & medical benefits
• Mental health & wellbeing support
• Financial health resources

Company Description

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. The Company is headquartered in London, UK, with a U.S. office in New Jersey. We believe mental health patients deserve the possibility of a better future. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).

COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.